 |
|
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
 |
 |
|
|
|
|
|
|
|
|
|
| 9/10/2010 |
J&J To Give Prostate Cancer Drug To All Patients In Trial
(New York, NY) -- An experimental new Johnson and Johnson drug meant to treat advanced prostate cancer is showing encouraging results. One clinical trial is going so well that the company has decided to start administering the medication, abiraterone acetate, to all the patients in the study. Johnson and Johnson-owned Courgar Biotechnology made that call after an independent monitoring committee said the drug worked so well at improving the survival rate of prostate cancer patients that it would be unethical not to give it to patients who were receiving the placebo in the clinical trial. The trial involved over a thousand patients with advanced metastatic prostate cancer who saw the disease progress even after chemotherapy. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|